Every material Form 8-K Ovid Therapeutics Inc. has filed with the SEC since April 20, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Ovid Therapeutics said its Chief Business and Financial Officer, Jeffrey Rona, will leave the company effective July 6, 2026, by mutual agreement. The Board appointed Charles Carter, the company's Senior Vice President of Finance and Financial Planning, as Chief Financial Officer, principal financial officer, principal accounting officer and secretary, effective the same day. The company states the departure was not due to any disagreement on accounting, financial statements, internal controls, operations, policies or practices.
Jeffrey Rona's separation date is July 6, 2026; the 8-K says he agreed to leave by mutual agreement, not over any accounting or control disagreement.
Charles Carter, age 59, takes the CFO, principal accounting officer and secretary roles, having served as SVP of Finance and Financial Planning since October 2024.
Carter's pay includes a $460,000 base salary, a target bonus of 35% of base salary, a 50,000-share RSU award vesting in two annual installments from July 6, 2027, and a $75,000 bonus opportunity.
Rona will receive 12 months of base salary, a prorated 2026 bonus and up to 12 months of COBRA benefits, and will provide advisory services through December 31, 2027.
Ovid Therapeutics said its board approved expanding the board to seven directors and appointing Dr. Anna Greka as a Class III director, effective June 15, 2026. Dr. Greka will also join the Compensation Committee and Science and Technology Committee, and will receive director pay under the company's existing policy.
Board approved the appointment on May 29, 2026, effective June 15, 2026, with a term expiring at the 2029 annual meeting.
Board size increases to seven directors effective June 15, 2026.
Dr. Greka, age 50, is a Professor of Medicine at Harvard Medical School and Mass General Brigham, and holds several Broad Institute roles.
Dr. Greka signed the company's standard indemnification agreement.
Ovid Therapeutics said Series A Warrants issued in its October 2025 private placement expired on April 17, 2026, and investors exercised them into common shares and pre-funded warrants. The exercises are expected to bring the company gross proceeds of approximately $53.9 million, and the filing notes the new shares and pre-funded warrants will add to the outstanding share count.
Warrants covered 38,481,325 common shares in total, expiring April 17, 2026.
Investors exercised into 33,597,860 common shares at $1.40 per share.
Investors also exercised into 4,883,464 pre-funded warrants at $1.399 per share, for gross proceeds of approximately $53.9 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Ovid Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →